FDA Approves Amneal’s Generic Suboxone to Treat Opioid Drug Dependence

Amneal Pharmaceuticals, LLC, the 7^th largest generic drug manufacturer in the U.S. market, has received U.S. FDA approval for one of the first generic versions of Suboxone^® sublingual tablets for maintenance treatment of opioid drug dependence. Generic buprenorphine hydrochloride (HCl) and naloxone HCl dihydrate sublingual tablets are now available in 2 mg/0.5 mg and 8 mg/2 mg strengths, both in 30-count bottles. 

http://www.news-medical.net/news/20130225/FDA-approves-Amneale28099s-generic-Suboxone-to-treat-opioid-drug-dependence.aspx

Source: NewsMedical.net – February 25, 2013

Note: On February 26, 2013 the FDA also approved Actavis’ generic Suboxone for treatment of opioid dependence. 

http://www.news-medical.net/news/20130226/FDA-approves-Actavise28099-generic-Suboxone-ANDA-to-treat-opioid-dependence.aspx

Source: NewsMedical.net – February 26, 2013